TY - JOUR
T1 - Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects
AU - Ho, Tzong Shiann
AU - Du, Pin Xian
AU - Su, Wen Yu
AU - Santos, Harvey M.
AU - Lin, Ya Lan
AU - Chou, Yi Yu
AU - Keskin, Batuhan Birol
AU - Pau, Chi Ho
AU - Syu, Guan Da
N1 - Funding Information:
This work was supported in part by the Ministry of Science and Technology , MOST- 110-2628-B-006-022 - (G.S.), MOST- 108-2320-B-006-054-MY2 (G.S.), SPARK NCKU (G.S.), MOST- 109-2327-B-006-005 - (G.S., T.H.), MOST- 110-2622-E-006-030 (T.H.), MOST- 110-2327-B-006-005 (T.H.), NHRI-110A1-MRCO-02212103 (T.H.), NCKUH-11002018 (T.H.), Medical Research Fund of Kaohsiung Armed Forces General Hospital KAFGH-D-108024 (Y.C.), KAFGH-D-109042 (Y.C.), KAFGH-D-110035 (Y.C.), KAFGH-D-111033 (Y.C.), and Headquarters of University Advancement at the National Cheng Kung University , Ministry of Education , Taiwan. We thank Prof. Chien-Sheng Chen for providing the microarray printer.
Funding Information:
This work was supported in part by the Ministry of Science and Technology, MOST-110-2628-B-006-022- (G.S.), MOST-108-2320-B-006-054-MY2 (G.S.), SPARK NCKU (G.S.), MOST-109-2327-B-006-005- (G.S. T.H.), MOST-110-2622-E-006-030 (T.H.), MOST-110-2327-B-006-005 (T.H.), NHRI-110A1-MRCO-02212103 (T.H.), NCKUH-11002018 (T.H.), Medical Research Fund of Kaohsiung Armed Forces General Hospital KAFGH-D-108024 (Y.C.), KAFGH-D-109042 (Y.C.), KAFGH-D-110035 (Y.C.), KAFGH-D-111033 (Y.C.), and Headquarters of University Advancement at the National Cheng Kung University, Ministry of Education, Taiwan. We thank Prof. Chien-Sheng Chen for providing the microarray printer.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/5/15
Y1 - 2022/5/15
N2 - SARS-CoV-2 is quickly evolving from wild-type to many variants and spreading around the globe. Since many people have been vaccinated with various types of vaccines, it is crucial to develop a high throughput platform for measuring the antibody responses and surrogate neutralizing activities against multiple SARS-CoV-2 variants. To meet this need, the present study developed a SARS-CoV-2 variant (CoVariant) array which consists of the extracellular domain of spike variants, e.g., wild-type, D614G, B.1.1.7, B.1.351, P.1, B.1.617, B.1.617.1, B.1.617.2, and B.1.617.3. A surrogate virus neutralization on the CoVariant array was established to quantify the bindings of antibody and host receptor ACE2 simultaneously to spike variants. By using a chimeric anti-spike antibody, we demonstrated a broad binding spectrum of antibodies while inhibiting the bindings of ACE2 to spike variants. To monitor the humoral immunities after vaccination, we collected serums from unvaccinated, partial, or fully vaccinated individuals with either mRNA-1273 or AZD1222 (ChAdOx1). The results showed partial vaccination increased the surrogate neutralization against all the mutants while full vaccination boosted the most. Although IgG, IgA, and IgM isotypes correlated with surrogate neutralizing activities, they behave differently throughout the vaccination processes. Overall, this study developed CoVariant arrays and assays for profiling the humoral responses which are useful for immune assessment, vaccine research, and drug development.
AB - SARS-CoV-2 is quickly evolving from wild-type to many variants and spreading around the globe. Since many people have been vaccinated with various types of vaccines, it is crucial to develop a high throughput platform for measuring the antibody responses and surrogate neutralizing activities against multiple SARS-CoV-2 variants. To meet this need, the present study developed a SARS-CoV-2 variant (CoVariant) array which consists of the extracellular domain of spike variants, e.g., wild-type, D614G, B.1.1.7, B.1.351, P.1, B.1.617, B.1.617.1, B.1.617.2, and B.1.617.3. A surrogate virus neutralization on the CoVariant array was established to quantify the bindings of antibody and host receptor ACE2 simultaneously to spike variants. By using a chimeric anti-spike antibody, we demonstrated a broad binding spectrum of antibodies while inhibiting the bindings of ACE2 to spike variants. To monitor the humoral immunities after vaccination, we collected serums from unvaccinated, partial, or fully vaccinated individuals with either mRNA-1273 or AZD1222 (ChAdOx1). The results showed partial vaccination increased the surrogate neutralization against all the mutants while full vaccination boosted the most. Although IgG, IgA, and IgM isotypes correlated with surrogate neutralizing activities, they behave differently throughout the vaccination processes. Overall, this study developed CoVariant arrays and assays for profiling the humoral responses which are useful for immune assessment, vaccine research, and drug development.
UR - http://www.scopus.com/inward/record.url?scp=85124392438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124392438&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2022.114067
DO - 10.1016/j.bios.2022.114067
M3 - Article
C2 - 35168024
AN - SCOPUS:85124392438
SN - 0956-5663
VL - 204
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
M1 - 114067
ER -